Cargando…

MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis

The Cancer Genome Atlas network has revealed that the ‘mesenchymal’ epithelial ovarian cancer (EOC) subtype represents the poorest outcome, indicating a crucial role of stromal cancer-associated fibroblasts (CAFs) in disease progression. The cooperative role of CAFs in EOC metastasis has long been r...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zongyuan, Xu, Sen, Jin, Ping, Yang, Xin, Li, Xiaoting, Wan, Dongyi, Zhang, Taoran, Long, Sixiang, Wei, Xiao, Chen, Gang, Meng, Li, Liu, Dan, Fang, Yong, Chen, Pingbo, Ma, Ding, Gao, Qinglei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122339/
https://www.ncbi.nlm.nih.gov/pubmed/27081703
http://dx.doi.org/10.18632/oncotarget.8726
_version_ 1782469559899389952
author Yang, Zongyuan
Xu, Sen
Jin, Ping
Yang, Xin
Li, Xiaoting
Wan, Dongyi
Zhang, Taoran
Long, Sixiang
Wei, Xiao
Chen, Gang
Meng, Li
Liu, Dan
Fang, Yong
Chen, Pingbo
Ma, Ding
Gao, Qinglei
author_facet Yang, Zongyuan
Xu, Sen
Jin, Ping
Yang, Xin
Li, Xiaoting
Wan, Dongyi
Zhang, Taoran
Long, Sixiang
Wei, Xiao
Chen, Gang
Meng, Li
Liu, Dan
Fang, Yong
Chen, Pingbo
Ma, Ding
Gao, Qinglei
author_sort Yang, Zongyuan
collection PubMed
description The Cancer Genome Atlas network has revealed that the ‘mesenchymal’ epithelial ovarian cancer (EOC) subtype represents the poorest outcome, indicating a crucial role of stromal cancer-associated fibroblasts (CAFs) in disease progression. The cooperative role of CAFs in EOC metastasis has long been recognized, but the mechanisms of stromal CAFs activation are still obscure. Therefore, we carried out an integrative analysis to identify the regulator genes that are responsible for CAFs activation in microdissected tumor stroma profiles. Here, we determined that myristoylated alanine-rich C-kinase substrate (MARCKS) was highly expressed in ovarian stroma, and was required for the differentiation and tumor promoting function of CAFs. Suppression of MARCKS resulted in the loss of CAF features, and diminished role of CAFs in supporting tumor cell growth in 3D organotypic cultures and in murine xenograft model. Mechanistically, we found that MARCKS maintained CAF activation through suppression of cellular senescence and activation of the AKT/Twist1 signaling. Moreover, high MARCKS expression was associated with poor patient survival in EOC. Collectively, our findings identify the potential of MARCKS inhibition as a novel stroma-oriented therapy in EOC.
format Online
Article
Text
id pubmed-5122339
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-51223392016-12-05 MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis Yang, Zongyuan Xu, Sen Jin, Ping Yang, Xin Li, Xiaoting Wan, Dongyi Zhang, Taoran Long, Sixiang Wei, Xiao Chen, Gang Meng, Li Liu, Dan Fang, Yong Chen, Pingbo Ma, Ding Gao, Qinglei Oncotarget Research Paper The Cancer Genome Atlas network has revealed that the ‘mesenchymal’ epithelial ovarian cancer (EOC) subtype represents the poorest outcome, indicating a crucial role of stromal cancer-associated fibroblasts (CAFs) in disease progression. The cooperative role of CAFs in EOC metastasis has long been recognized, but the mechanisms of stromal CAFs activation are still obscure. Therefore, we carried out an integrative analysis to identify the regulator genes that are responsible for CAFs activation in microdissected tumor stroma profiles. Here, we determined that myristoylated alanine-rich C-kinase substrate (MARCKS) was highly expressed in ovarian stroma, and was required for the differentiation and tumor promoting function of CAFs. Suppression of MARCKS resulted in the loss of CAF features, and diminished role of CAFs in supporting tumor cell growth in 3D organotypic cultures and in murine xenograft model. Mechanistically, we found that MARCKS maintained CAF activation through suppression of cellular senescence and activation of the AKT/Twist1 signaling. Moreover, high MARCKS expression was associated with poor patient survival in EOC. Collectively, our findings identify the potential of MARCKS inhibition as a novel stroma-oriented therapy in EOC. Impact Journals LLC 2016-04-13 /pmc/articles/PMC5122339/ /pubmed/27081703 http://dx.doi.org/10.18632/oncotarget.8726 Text en Copyright: © 2016 Yang et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Yang, Zongyuan
Xu, Sen
Jin, Ping
Yang, Xin
Li, Xiaoting
Wan, Dongyi
Zhang, Taoran
Long, Sixiang
Wei, Xiao
Chen, Gang
Meng, Li
Liu, Dan
Fang, Yong
Chen, Pingbo
Ma, Ding
Gao, Qinglei
MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis
title MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis
title_full MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis
title_fullStr MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis
title_full_unstemmed MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis
title_short MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis
title_sort marcks contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122339/
https://www.ncbi.nlm.nih.gov/pubmed/27081703
http://dx.doi.org/10.18632/oncotarget.8726
work_keys_str_mv AT yangzongyuan marckscontributestostromalcancerassociatedfibroblastactivationandfacilitatesovariancancermetastasis
AT xusen marckscontributestostromalcancerassociatedfibroblastactivationandfacilitatesovariancancermetastasis
AT jinping marckscontributestostromalcancerassociatedfibroblastactivationandfacilitatesovariancancermetastasis
AT yangxin marckscontributestostromalcancerassociatedfibroblastactivationandfacilitatesovariancancermetastasis
AT lixiaoting marckscontributestostromalcancerassociatedfibroblastactivationandfacilitatesovariancancermetastasis
AT wandongyi marckscontributestostromalcancerassociatedfibroblastactivationandfacilitatesovariancancermetastasis
AT zhangtaoran marckscontributestostromalcancerassociatedfibroblastactivationandfacilitatesovariancancermetastasis
AT longsixiang marckscontributestostromalcancerassociatedfibroblastactivationandfacilitatesovariancancermetastasis
AT weixiao marckscontributestostromalcancerassociatedfibroblastactivationandfacilitatesovariancancermetastasis
AT chengang marckscontributestostromalcancerassociatedfibroblastactivationandfacilitatesovariancancermetastasis
AT mengli marckscontributestostromalcancerassociatedfibroblastactivationandfacilitatesovariancancermetastasis
AT liudan marckscontributestostromalcancerassociatedfibroblastactivationandfacilitatesovariancancermetastasis
AT fangyong marckscontributestostromalcancerassociatedfibroblastactivationandfacilitatesovariancancermetastasis
AT chenpingbo marckscontributestostromalcancerassociatedfibroblastactivationandfacilitatesovariancancermetastasis
AT mading marckscontributestostromalcancerassociatedfibroblastactivationandfacilitatesovariancancermetastasis
AT gaoqinglei marckscontributestostromalcancerassociatedfibroblastactivationandfacilitatesovariancancermetastasis